Fundraising Fox
/Companies
Sign in

OrsoBio

Menlo Park, US · Founded 2020 · Delaware corporation · 4 known investors

Find your way into OrsoBio

Sign up to see every warm intro you have to OrsoBio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the OrsoBio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways. The company targets patients with metabolic diseases through precision therapeutic approaches.

BiotechDeep TechMedical Devices

Founders & leadership

MSMani Subramanian
Mani SubramanianCEO
GG
Gangadhara GanapatiExecutive
DS
Dr. Subramanian
DM
Dr. Myers

Board

MYMatthew Young
Matthew YoungBoard directorManaging Director at Longitude Capital
SASrinivas Akkaraju
Srinivas AkkarajuBoard directorGeneral Partner at Samsara BioCapital
CF
Cory FreedlandBoard directorInvestor at Samsara BioCapital
EF
Edward FlemingBoard director
EREvan Rachlin
Evan RachlinBoard directorGeneral Partner at Ascenta Capital
MM
Muzammil MansuriBoard director

Investors · 4

Longitude Capital✓ confirmed by OrsoBioMenlo Park · $10M – $30M

How we know: the company's own site · Longitude Capital's portfolio page · press coverage · the VCSheet dataset · Not right? Tell us

Samsara BioCapital✓ confirmed by OrsoBioMenlo Park

How we know: Samsara BioCapital's portfolio page · the company's own site · board seat on SEC Form D · press coverage · Not right? Tell us

F-Prime Capital✓ confirmed by OrsoBioCambridge · $3M – $10M

How we know: the company's own site · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$124.6M disclosed across 2 rounds · 2023–2024

▶$40MraisedAug 2024 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew YoungDirector
  • Mani SubramanianExecutive Officer, Director
  • Srinivas AkkarajuDirector
  • Cory FreedlandDirector
  • Edward FlemingDirector
  • Evan RachlinDirector
  • Muzammil MansuriDirector
  • Gangadhara GanapatiExecutive Officer, Director
Offering amount
$67M
Amount sold
$40M
First sale
Aug 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$84.6MraisedNov 2023 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Gangadhara GanapatiExecutive Officer, Director
  • Mani SubramanianExecutive Officer, Director
  • Cory FreedlandDirector
  • Muzammil MansuriDirector
  • Matthew YoungDirector
  • Edward FlemingDirector
  • Srinivas AkkarajuDirector
Offering amount
$84.6M
Amount sold
$84.6M
First sale
Oct 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
BridgebioBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

Companies working in the same space as OrsoBio.

In the news

Exclusive: Lilly-backed OrsoBio raises $67M for slate of obesity drugs as combinations take root - OrsoBioorsobio.com · Sep 2024OrsoBio Announces Oversubscribed $67 Million Series B Financing to Accelerate Mitochondrial Protonophore Portfolio Targeting Obesity and Associated Disorders - OrsoBioorsobio.com · Sep 2024

Frequently asked questions

What does OrsoBio do?
OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways. The company targets patients with metabolic diseases through precision therapeutic approaches.
Who are OrsoBio's investors?
OrsoBio's investors include Ascenta Capital, Longitude Capital, Samsara BioCapital, F-Prime Capital.
How much funding has OrsoBio raised?
OrsoBio has disclosed $124.6M raised across 2 rounds.
Where is OrsoBio headquartered?
OrsoBio is headquartered in Menlo Park, US.